Journal: Human Vaccines & Immunotherapeutics

Article Title: Emerging trends of research on mRNA vaccines: A co-citation analysis

doi: 10.1080/21645515.2022.2110409

Figure Lengend Snippet: Brief information of clusters in the co-citation network.

Article Snippet: #8 , 50 , Hirotsu, Y (2021) Robust antibody responses to the bnt162b2 mRNA vaccine occur within a week after the first dose in previously infected individuals and after the second dose in uninfected individuals , 116 , - , 0.06 , Dan JM2021Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , SCIENCE.

Techniques: Activity Assay, Activation Assay, Virus, Expressing, Molecular Weight, Polymer, Infection, Wilms Tumor Assay, Bioprocessing, Variant Assay, Vaccines

Journal: Human Vaccines & Immunotherapeutics

Article Title: Emerging trends of research on mRNA vaccines: A co-citation analysis

doi: 10.1080/21645515.2022.2110409

Figure Lengend Snippet: Main citing articles and cited references in each cluster.

Article Snippet: #8 , 50 , Hirotsu, Y (2021) Robust antibody responses to the bnt162b2 mRNA vaccine occur within a week after the first dose in previously infected individuals and after the second dose in uninfected individuals , 116 , - , 0.06 , Dan JM2021Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , SCIENCE.

Techniques: Vaccines, Activity Assay, In Vivo, Immunopeptidomics, Molecular Weight, Polymer, In Vitro, Synthesized, Virus, Infection, Selection, Variant Assay, Expressing, Activation Assay, Modification, Inhibition, Bioprocessing, Wilms Tumor Assay, Quantitative Proteomics, Gene Expression, Generated, RNA Sequencing, Genome Wide, Electroporation, Plasmid Preparation, Control, Comparison

Journal: Internal Medicine

Article Title: Internal Medicine Year in Review 2022

doi: 10.2169/internalmedicine.2266-23

Figure Lengend Snippet: COVID-19 Related Articles (in Order of Number of Citations).

Article Snippet: 11 , Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G , Hibino Makoto, et al , 4 , 2022 , 61 , 6 , 811 , 819.

Techniques: Control, Comparison, Variant Assay, Infection

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Characteristics of the studies describing the effectiveness and safety of SARS‐CoV‐2 vaccines in inflammatory Bowel Disease (IBD) patients

Article Snippet: Kappelman et al,2021 , Prospective, observational cohort , United States , Survey‐based study of 317 IBD patients recruited via social media, education and outreach efforts of Crohn’s and Colitis foundation , Age ≥ 16 years with diagnosis of IBD diagnosis with receipt of 1 or more doses of SARS‐CoV‐2 vaccines and followed up to 18 months , BNT 162b2 Vaccine and mRNA‐1273 vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Vaccines, Biomarker Discovery, Binding Assay, Infection, Medications, Enzyme-linked Immunosorbent Assay

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Studies describing seroconversion after SARS‐CoV‐2 vaccination in inflammatory Bowel Disease patients

Article Snippet: Kappelman et al,2021 , Prospective, observational cohort , United States , Survey‐based study of 317 IBD patients recruited via social media, education and outreach efforts of Crohn’s and Colitis foundation , Age ≥ 16 years with diagnosis of IBD diagnosis with receipt of 1 or more doses of SARS‐CoV‐2 vaccines and followed up to 18 months , BNT 162b2 Vaccine and mRNA‐1273 vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Medications, Vaccines

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Outcomes of studies describing breakthrough CoV‐19 infection in vaccinated inflammatory Bowel Disease (IBD) patients

Article Snippet: Kappelman et al,2021 , Prospective, observational cohort , United States , Survey‐based study of 317 IBD patients recruited via social media, education and outreach efforts of Crohn’s and Colitis foundation , Age ≥ 16 years with diagnosis of IBD diagnosis with receipt of 1 or more doses of SARS‐CoV‐2 vaccines and followed up to 18 months , BNT 162b2 Vaccine and mRNA‐1273 vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Infection, Comparison, Control

Journal: Biomedicines

Article Title: Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

doi: 10.3390/biomedicines9111740

Figure Lengend Snippet: Summary of SARS-CoV-2 vaccine strategies with their advantages and limitations.

Article Snippet: 2 , mRNA vaccine , Easy to design, lower risk of accidental infection than viral vaccines , Carrier required to stabilize and pack naked RNA , BNT162b2, mRNA-1273, ARCoV, CureVac (Tübingen, Germany).

Techniques: Immunopeptidomics, Vaccines, Infection, Recombinant, Plasmid Preparation, Control, Virus

Journal: Biomedicines

Article Title: Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

doi: 10.3390/biomedicines9111740

Figure Lengend Snippet: Forerunners in clinical trials: possible candidates for future.

Article Snippet: 2 , mRNA vaccine , Easy to design, lower risk of accidental infection than viral vaccines , Carrier required to stabilize and pack naked RNA , BNT162b2, mRNA-1273, ARCoV, CureVac (Tübingen, Germany).

Techniques: Clinical Proteomics, Vaccines, Recombinant, Adjuvant, Modification, Variant Assay, Virus, Binding Assay, In Vitro, Activity Assay, Plasmid Preparation, Formulation

Journal: Biomedicines

Article Title: Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

doi: 10.3390/biomedicines9111740

Figure Lengend Snippet: Vaccines currently in the final phase of clinical trial. Protein subunit vaccines (9) dominate the list followed by mRNA vaccine and recombinant viral vector (3 each). Each of live attenuated, inactivated, virus like particles, and DNA vaccines are in the final phase trial.

Article Snippet: 2 , mRNA vaccine , Easy to design, lower risk of accidental infection than viral vaccines , Carrier required to stabilize and pack naked RNA , BNT162b2, mRNA-1273, ARCoV, CureVac (Tübingen, Germany).

Techniques: Vaccines, Recombinant, Plasmid Preparation, Virus